The principal focus in this report is on bone and joint applications; however, other regenerative applications such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care are important and are briefly covered to underscore the larger importance of regenerative therapies. Stem–cell research is an important component of the sector as well. For example, the successful differentiation of embryonic stem cells into specific cell types is widely sought as a means to treat traumatic spinal–cord injury, as well as diseases such as diabetes, Duchenne muscular dystrophy, heart disease, and vision and hearing loss.
OBJECTIVES AND GOALS OF STUDY
This report focuses on the bone– and joint–related applications of and markets for the various categories of regenerative medicine products currently available and projected to be introduced during the five–year forecast period from 2013 through 2018. Market drivers discussed include the status of R&D and what is likely to issue from R&D in the way of actual products and therapies. Other market drivers include the incidence, and rate of growth, of diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of non–autograft products by physicians; and innovative devices that incorporate bone– and cartilage–growth–stimulating agents in a regenerative appliance. Products discussed include bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.
Copyright©2012 Vocus, Inc.
All rights reserved